What Trump’s Covid-19 experience reveals about our pandemic response
Did Trump receive the "best care possible"? Or was he overtreated? More
Did Trump receive the "best care possible"? Or was he overtreated? More
A study late last week found that convalescent plasma (CP) treatment did not significantly reduce mortality, but improved hospital discharge rates for patients 65 and older. More
At a presentation for the Massachusetts Health Data Collaborative, Vikas Saini and Shannon Brownlee discussed why they created the Lown Hospitals Index, how the metrics were developed, and what the results show about hospitals in Massachusetts. Watch the full presentation here! More
The Trump Administration is poised to make a settlement with Purdue Pharma that it can claim as a victory for opioid victims. But the proposed outcome would leave the company’s owners enormously wealthy—and off the hook for good. More
This Viewpoint proposes that varying combinations of evidence, physician influence, and economics guide the continuation or de-adoption of low-value health services and can help organize and prioritize policy initiatives to drive down the prevalence of wasteful care. More
Many cardiologists recognize that placing coronary stents for stable heart disease has limited clinical benefit for patients. But low-value stents are still common -- how can we change this practice? New research in JAMA Internal Medicine provides some suggestions. More
How can we measure what really matters in primary care? In an essay in KevinMD, Dr. Michelle-Linh Nguyen offers a vision for better metrics in primary care. More
Bronchiolitis is one of the most common reasons for pediatric hospitalization in the United States, incurring costs of $734 million each year. More
Paid even less than low-wage doctors’ scribes in the United States, remote note takers in India gain a foothold in a rapidly expanding industry. More
The president said at Tuesday’s debate that he lowered insulin prices. That’s not true — and, for some, the drug’s expense is a fatal barrier. More
The Spotlight team gathered data from over 1 million death certificates in Massachusetts and found a disturbing connection between wealth and age of death. More
Dr. Ala Stanford was frustrated by systemic barriers preventing Black residents from getting tests. She created the Black Doctors COVID-19 Consortium and sends mobile test units into neighborhoods. More
For people with diabetes, a thicket of biological and socioeconomic factors make them more likely to suffer severe illness and die of Covid-19. More
Amid the COVID-19 pandemic, hospice's new H Word is Hero! Stripped of the illusion of security, the public sees the immediate and enduring value of palliative care, home health care, nursing home care, and hospice. More
Enormous drug company profits are the primary driver of soaring prescription drug prices in America, according to a damning investigation that Democrats on the House Oversight Committee began releasing Wednesday. More
Expectant mothers have long been excluded from clinical trials. Some experts say this practice needs to change. More
This Viewpoint highlights 2 ways, based on insights from industries outside health care, to increase participation in and benefits of surgical bundles. More
Thousands of patients in L.A. County's public hospital system face long, sometimes deadly waits to see specialists, a Times investigation has found. The system serves primarily the region's poorest and most vulnerable residents. More
The UMass Memorial HealthAlliance-Clinton Hospital campus in Leominster leads the state in the new Lown Institute Hospitals Index, a ranking of 3,300 hospitals and 300 hospital systems launched this summer. “It’s not necessarily the usual suspects that you’re going to find at the top of these rankings,” said Shannon Brownlee, the institute’s senior vice president. Lown Institute President Dr. Vikas Saini said the index is meant to help shape a discussion around health-care quality and unearth new ideas, rather than serve as a shopping guide for consumers. More
“Our study shows that there are evidence gaps that the FDA needs to address in approving new opioids,” said study co-author Thomas Moore. More